EMPLOYMENT AGREEMENTEmployment Agreement • February 12th, 2019 • Bison Capital Acquisition Corp. • Pharmaceutical preparations • Delaware
This EMPLOYMENT AGREEMENT (the “Agreement”) dated as of Jan 16th, 2019 (the “Effective Date”) is made by and between Xynomic Pharmaceuticals, Inc. (the “Company”) and Sophia Paspal (the “Employee”).
AMENDMENT TO AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • February 12th, 2019 • Bison Capital Acquisition Corp. • Pharmaceutical preparations
This AMENDMENT TO AGREEMENT AND PLAN OF MERGER, is entered into as of February 11, 2019 (this “Amendment”), by and among Xynomic Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Bison Capital Acquisition Corp., a British Virgin Islands company limited by shares (“Parent”), Bison Capital Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent (the “Merger Sub”), and Yinglin Mark Xu (“XU”), an individual residing in Shanghai, China, solely in his capacity as the representative for the Company Stockholders (the “Stockholder Representative”).
LICENSE AGREEMENT between PHARMACYCLICS LLC and XYNOMIC PHARMACEUTICALS, INC. Dated as of February 23, 2017License Agreement • February 12th, 2019 • Bison Capital Acquisition Corp. • Pharmaceutical preparations • New York
This License Agreement (the “Agreement”) is made and entered into effective as of February 23, 2017 (the “Effective Date”) by and between Pharmacyclics LLC, a Delaware limited liability company wholly owned by AbbVie Inc. (“Pharmacyclics”), and Xynomic Pharmaceuticals, Inc., a Wyoming corporation (“Xynomic”). Pharmacyclics and Xynomic are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
PATENT ASSIGNMENT AND LICENSING AGREEMENTPatent Assignment and Licensing Agreement • February 12th, 2019 • Bison Capital Acquisition Corp. • Pharmaceutical preparations • New York
This Patent Assignment and Licensing Agreement (“Agreement”) is entered into on the date of last signature hereto (“Effective Date”)
LICENSING AGREEMENTLicensing Agreement • February 12th, 2019 • Bison Capital Acquisition Corp. • Pharmaceutical preparations • New York
Boehringer Ingelheim International GmbH (“BII”), a German limited liability company, with offices at Binger Straße 173, 55216 Ingelheim am Rhein, Germany; and
Bridge Loan AgreementBridge Loan Agreement • February 12th, 2019 • Bison Capital Acquisition Corp. • Pharmaceutical preparations
This Agreement (the “Agreement”) is made and entered into effective as of August 15, 2017 (the “Effective Date”) by and between Xynomic Pharmaceuticals, Inc., a Wyoming corporation (“Xynomic”) and Mr. Yinglin Mark Xu (“Xu”) residing at 2842 Catalino St, San Mateo, CA 94403, US. Xynomic and Xu are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Amended Bridge Loan AgreementBridge Loan Agreement • February 12th, 2019 • Bison Capital Acquisition Corp. • Pharmaceutical preparations
This Agreement (the “Agreement”) is made and entered into effective as of August 31, 2017 (the “Effective Date”) by and between Xynomic Pharmaceuticals, Inc., a Wyoming corporation (“Xynomic”) and Mr. Yinglin Mark Xu (“Xu”) residing at 2842 Catalino St, San Mateo, CA 94403, US. Xynomic and Xu are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
